16082-64-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-N-quinoline-8-yl-benzenesulfonam is used as a building block for the synthesis of pharmaceuticals due to its potential antitumor and antimalarial properties. It is valued for its ability to inhibit carbonic anhydrase, which is implicated in various diseases, making it a key component in the development of new drugs for such conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Amino-N-quinoline-8-yl-benzenesulfonam serves as a fundamental component in the creation of new agrochemicals, leveraging its potential to combat various pests and diseases affecting crops.
Used in Anticancer Applications:
2-Amino-N-quinoline-8-yl-benzenesulfonam is utilized as an anticancer agent, showing promise in the treatment of various types of cancer. Its potential to inhibit specific enzymes and biological pathways involved in tumor growth and progression makes it a candidate for further research and development in oncology.
Used in Antimalarial Applications:
2-AMINO-N-QUINOLINE-8-YL-BENZENESULFONAM is also used as an antimalarial agent, given its potential to combat the Plasmodium parasites responsible for malaria, a disease affecting millions worldwide.
Used in Treatment of Diabetes and Infectious Diseases:
2-Amino-N-quinoline-8-yl-benzenesulfonam has been studied for its potential in treating diabetes and infectious diseases, indicating its broad-spectrum applicability in medicine.
Used as Anti-inflammatory and Analgesic Agent:
Furthermore, it has been investigated for its potential as an anti-inflammatory and analgesic agent, suggesting its use in managing pain and inflammation associated with various conditions.

InChI:InChI=1/C15H13N3O2S/c16-12-7-1-2-9-14(12)21(19,20)18-13-8-3-5-11-6-4-10-17-15(11)13/h1-10,18H,16H2

Upstream product

• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 578-66-5 8-amino quinoline 
• 21868-77-9 CU-153 

Downstream Products

• 21868-80-4 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide 
• 1394081-89-0 N-[2-(Quinolin-8-ylsulfamoyl)-phenyl]-isobutyramide 
• 1393712-12-3 1-(2-N-quinolin-8-yl-benzenesulfonamino-acetamide)-4,7,10-tris(tert-butoxy-carbonyl-methyl)-1,4,7,10-tetraaza-cyclododecane 
• 1393712-14-5 1-(2-N-quinolin-8-yl-benzenesulfonamino-acetamide)-4,7,10-tris(acetic acid)-1,4,7,10-tetraaza-cyclododecane 
• 1393712-09-8 N-(quinolin-8-yl)-2-(2-chloroacetyl)-amino-benzenesulfonamide 

Relevant academic research and scientific papers

Novel Sulfonaminoquinoline Hepcidin Antagonists

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

COMPOUNDS THAT INHIBIT NFκB ACTIVITY

The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment o

Convenient preparation of N-8-quinolinyl benzenesultams as novel NF-κB inhibitors

An efficient synthesis of a series of N-8-quinolinyl benzenesultams as novel NF-κB inhibitors was described via diazotization-induced cyclization of easily accessible N-8-quinolinyl-2-aminobenzenesulfonamides.

Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation

We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NFκB pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in bot